NEW YORK (GenomeWeb News) - Lexicon Genetics today said it has entered into agreements with unspecified investors to purchase up to 10,582,011 shares of its stock.
The Woodlands, Texas-based biopharmaceutical company said "select institutional investors" agreed to purchase the stock at a price of $3.78 per share, and that it expects net proceeds of up to $37.5 million.
The agents for the placement were Banc of America Securities and Lazard Capital Markets.
Registering provides access to this and other free content.
Already have an account?Login Now.
The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.
In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.
Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.
A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.